Trial Profile
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms PROTECT
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals
- 04 Jul 2022 Results of meta analysis from KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE, presented at the 37th Congress of the European Association of Urology
- 16 May 2022 Systemic and meta-analysis from six trials (KEYNOTE-564, S-TRAC, ASSURE, PROTECT, ATLAS, and SORCE) presented at the 117th Annual Meeting of the American Urological Association
- 13 Sep 2021 Data from this study were used to assess prognostic gene expression in the RCC TME from patients with high-risk, localized disease, presented at the 116th Annual Meeting of the American Urological Association.